Halozyme Enters Global Exclusive Collaboration with Oruka
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 06 2026
0mins
Halozyme (HALO) and Oruka Therapeutics (ORKA) announced that Halozyme's wholly-owned subsidiary, Halozyme Hypercon, has entered into a global exclusive collaboration and license agreement with Oruka. Oruka has licensed Halozyme's Hypercon technology for use with ORKA-001, in development for psoriasis and related inflammatory diseases, and up to one additional target. Hypercon is an innovative microparticle technology that allows for hyperconcentration of drugs and biologics, reducing injection volume for a given dose and supporting more convenient, patient-friendly administration. Under the terms of the agreement, Oruka will make an upfront payment to Halozyme and potential future milestone payments. Halozyme will also be eligible to receive mid-single digit royalties on net sales of products developed using the Hypercon technology.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HALO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HALO
Wall Street analysts forecast HALO stock price to rise
5 Analyst Rating
3 Buy
1 Hold
1 Sell
Moderate Buy
Current: 68.180
Low
56.00
Averages
78.50
High
90.00
Current: 68.180
Low
56.00
Averages
78.50
High
90.00
About HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Halozyme Reports Strong Q1 2026 Earnings and Strategic Outlook
- Strong Financial Performance: Halozyme reported total revenue of $377 million for Q1 2026, a 42% year-over-year increase, with royalty revenues reaching $241 million, up 43%, indicating sustained market demand for its ENHANZE portfolio and bolstering confidence in future profitability.
- Capital Return Plan: The company announced a new $1 billion share buyback authorization, expecting to repurchase at least $400 million of shares in 2026, a move that not only enhances shareholder value but also reflects management's confidence in the company's financial health, projecting net leverage to drop to approximately 1.2x by the end of 2026.
- Long-Term Profitability Goals: Management reaffirmed that adjusted EBITDA margins will exceed 65% during the 2026 to 2028 period, with expectations for ENHANZE royalties to surpass $1 billion for the first time in 2026, laying a solid foundation for future growth.
- Clinical Progress Adjustment: The timeline for Hypercon's Phase I clinical trial starts has been shifted from late 2026 to the first half of 2027, which may temporarily impact investor confidence but reflects the company's cautious approach to ensuring product quality and manufacturing capabilities.
See More
Halozyme (HALO) Q1 2026 Earnings Transcript
See More
FDA Approves Label Expansion for Vyvgart in Myasthenia Gravis
- Label Expansion Approval: The FDA has approved the label expansion for Vyvgart and Vyvgart Hytrulo in myasthenia gravis, allowing a broader section of adults to receive this therapy, which is expected to significantly enhance market coverage and sales.
- Strong Sales Performance: Argenx reported over $4 billion in global sales last year, indicating Vyvgart's robust market performance, and this label expansion is likely to further drive sales growth and solidify its market leadership.
- Clinical Research Support: The label expansion is backed by the results of the Phase 3 ADAPT SERON study, demonstrating Vyvgart's efficacy for all serotypes of myasthenia gravis patients, which bolstered the FDA's confidence in the approval.
- Collaborative Development Advantage: Vyvgart Hytrulo, the injectable version developed in partnership with Halozyme, leverages Halozyme's technological advantages, which is expected to enhance patient convenience and adherence, further expanding market potential.
See More
Halozyme Therapeutics Q1 Earnings Announcement Scheduled
- Earnings Release Date: Halozyme Therapeutics (HALO) is set to announce its Q1 earnings on May 11th after market close, with a consensus EPS estimate of $1.52, reflecting a 36.9% year-over-year growth, indicating sustained improvement in profitability.
- Revenue Expectations: Analysts forecast that Halozyme's Q1 revenue will reach $359.05 million, representing a 35.5% year-over-year increase, which underscores the strong market demand and growth potential in the drug delivery technology sector.
- Performance Beat Record: Over the past two years, HALO has exceeded EPS and revenue estimates 88% of the time, a track record that not only boosts investor confidence but also lays a solid foundation for future growth.
- Estimate Revision Dynamics: Despite no upward revisions in EPS and revenue estimates over the last three months, with four downward adjustments each, this may reflect a cautious market sentiment regarding short-term performance, although the company remains competitively strong.
See More
Halozyme and GSK Reach Drug Delivery Technology Licensing Agreement
- Agreement Reached: Halozyme Therapeutics (HALO) has entered into a global collaboration and licensing agreement with GSK (GSK) to advance subcutaneously delivered cancer drugs, marking a strategic partnership in cancer treatment.
- Clinical Trial Initiation: Under the agreement, the companies plan to initiate their first clinical trial this year, focusing on developing injectable versions of antibody-drug conjugates, which is expected to accelerate the market introduction of new therapies.
- Future Development Options: Halozyme will provide GSK with an option to develop Enhanze-based therapies targeting other drug targets in the future, indicating the potential for long-term collaboration in innovative drug development.
- Financial Terms Undisclosed: While the agreement includes undisclosed upfront payments and royalties on net sales of Enhanze-based products, specific financial terms remain confidential, which may affect market expectations regarding the collaboration.
See More
Halozyme Enters ENHANZE® Agreement with GSK for ADC Targets
- Global Collaboration Agreement: Halozyme has entered into a global collaboration and license agreement with GSK, granting GSK access to its ENHANZE® drug delivery technology for the development of subcutaneous administration of multiple oncology targets, including antibody-drug conjugates (ADCs), marking a strategic expansion for Halozyme in oncology.
- Clinical Trial Plans: The first clinical trial is projected to initiate in 2026, and this collaboration not only aims to advance the development of several oncology therapeutics but also has the potential to significantly enhance patient treatment experiences by reducing treatment burdens.
- Market Potential Expansion: By partnering with GSK, Halozyme is set to further expand its high-margin royalty revenue streams, enhancing its competitive position in the rapidly growing oncology market, which is expected to attract more pharmaceutical companies to its technology.
- Technological Innovation and Application: The ENHANZE® technology has been utilized in ten commercialized products across over 100 global markets, and the collaboration with GSK is anticipated to drive the development of more innovative drugs, further solidifying Halozyme's leadership position in the biopharmaceutical sector.
See More
Halozyme Reports Strong Q1 2026 Earnings and Strategic Outlook
- Strong Financial Performance: Halozyme reported total revenue of $377 million for Q1 2026, a 42% year-over-year increase, with royalty revenues reaching $241 million, up 43%, indicating sustained market demand for its ENHANZE portfolio and bolstering confidence in future profitability.
- Capital Return Plan: The company announced a new $1 billion share buyback authorization, expecting to repurchase at least $400 million of shares in 2026, a move that not only enhances shareholder value but also reflects management's confidence in the company's financial health, projecting net leverage to drop to approximately 1.2x by the end of 2026.
- Long-Term Profitability Goals: Management reaffirmed that adjusted EBITDA margins will exceed 65% during the 2026 to 2028 period, with expectations for ENHANZE royalties to surpass $1 billion for the first time in 2026, laying a solid foundation for future growth.
- Clinical Progress Adjustment: The timeline for Hypercon's Phase I clinical trial starts has been shifted from late 2026 to the first half of 2027, which may temporarily impact investor confidence but reflects the company's cautious approach to ensuring product quality and manufacturing capabilities.
See More
Halozyme (HALO) Q1 2026 Earnings Transcript
See More
FDA Approves Label Expansion for Vyvgart in Myasthenia Gravis
- Label Expansion Approval: The FDA has approved the label expansion for Vyvgart and Vyvgart Hytrulo in myasthenia gravis, allowing a broader section of adults to receive this therapy, which is expected to significantly enhance market coverage and sales.
- Strong Sales Performance: Argenx reported over $4 billion in global sales last year, indicating Vyvgart's robust market performance, and this label expansion is likely to further drive sales growth and solidify its market leadership.
- Clinical Research Support: The label expansion is backed by the results of the Phase 3 ADAPT SERON study, demonstrating Vyvgart's efficacy for all serotypes of myasthenia gravis patients, which bolstered the FDA's confidence in the approval.
- Collaborative Development Advantage: Vyvgart Hytrulo, the injectable version developed in partnership with Halozyme, leverages Halozyme's technological advantages, which is expected to enhance patient convenience and adherence, further expanding market potential.
See More
Halozyme Therapeutics Q1 Earnings Announcement Scheduled
- Earnings Release Date: Halozyme Therapeutics (HALO) is set to announce its Q1 earnings on May 11th after market close, with a consensus EPS estimate of $1.52, reflecting a 36.9% year-over-year growth, indicating sustained improvement in profitability.
- Revenue Expectations: Analysts forecast that Halozyme's Q1 revenue will reach $359.05 million, representing a 35.5% year-over-year increase, which underscores the strong market demand and growth potential in the drug delivery technology sector.
- Performance Beat Record: Over the past two years, HALO has exceeded EPS and revenue estimates 88% of the time, a track record that not only boosts investor confidence but also lays a solid foundation for future growth.
- Estimate Revision Dynamics: Despite no upward revisions in EPS and revenue estimates over the last three months, with four downward adjustments each, this may reflect a cautious market sentiment regarding short-term performance, although the company remains competitively strong.
See More
Halozyme and GSK Reach Drug Delivery Technology Licensing Agreement
- Agreement Reached: Halozyme Therapeutics (HALO) has entered into a global collaboration and licensing agreement with GSK (GSK) to advance subcutaneously delivered cancer drugs, marking a strategic partnership in cancer treatment.
- Clinical Trial Initiation: Under the agreement, the companies plan to initiate their first clinical trial this year, focusing on developing injectable versions of antibody-drug conjugates, which is expected to accelerate the market introduction of new therapies.
- Future Development Options: Halozyme will provide GSK with an option to develop Enhanze-based therapies targeting other drug targets in the future, indicating the potential for long-term collaboration in innovative drug development.
- Financial Terms Undisclosed: While the agreement includes undisclosed upfront payments and royalties on net sales of Enhanze-based products, specific financial terms remain confidential, which may affect market expectations regarding the collaboration.
See More
Halozyme Enters ENHANZE® Agreement with GSK for ADC Targets
- Global Collaboration Agreement: Halozyme has entered into a global collaboration and license agreement with GSK, granting GSK access to its ENHANZE® drug delivery technology for the development of subcutaneous administration of multiple oncology targets, including antibody-drug conjugates (ADCs), marking a strategic expansion for Halozyme in oncology.
- Clinical Trial Plans: The first clinical trial is projected to initiate in 2026, and this collaboration not only aims to advance the development of several oncology therapeutics but also has the potential to significantly enhance patient treatment experiences by reducing treatment burdens.
- Market Potential Expansion: By partnering with GSK, Halozyme is set to further expand its high-margin royalty revenue streams, enhancing its competitive position in the rapidly growing oncology market, which is expected to attract more pharmaceutical companies to its technology.
- Technological Innovation and Application: The ENHANZE® technology has been utilized in ten commercialized products across over 100 global markets, and the collaboration with GSK is anticipated to drive the development of more innovative drugs, further solidifying Halozyme's leadership position in the biopharmaceutical sector.
See More
